1 Guidance

1 Guidance

The recommendation wording has been updated in line with NICE's existing wording conventions and the wording used in NICE technology appraisal guidance 293. See Changes after publication for more information.

1.1 Romiplostim is recommended as an option for treating adults with chronic immune (idiopathic) thrombocytopenic purpura, within its marketing authorisation (that is, in adults who have had a splenectomy and whose condition is refractory to other treatments, or as a second-line treatment in adults who have not had a splenectomy because surgery is contraindicated), only if:

  • their condition is refractory to standard active treatments and rescue therapies, or

  • they have severe disease and a high risk of bleeding that needs frequent courses of rescue therapies


  • if the manufacturer makes romiplostim available with the discount agreed in the patient access scheme.

1.2 People currently receiving romiplostim whose disease does not meet the criteria in 1.1 should be able to continue treatment until they and their clinician consider it appropriate to stop.

  • National Institute for Health and Care Excellence (NICE)